MOMA Therapeutics

International Day of Women and Girls in Science is about recognizing the trailblazing women everywhere who make vital contributions to the field day in and day out. #Science wouldn't be where it is without its female voices. To the next generation of #WomeninScience: Some of our stellar female MOMAtes have important messages for you below!

At MOMA we’re all about celebrating our successes and the people who make them possible. For our end-of-year celebration, we hosted our own “MOSCARS”— a MOMA spin on the Oscars—to recognize the outstanding contributions of our team. MOMAtes voted to honor individuals and teams across eight awards categories, like Science with a Purpose, Courage to Act, and Team of the Year. Beyond the awards, the night was all about coming together, enjoying great food, celebrating our shared successes, and reflecting on another incredible year.

Coming up on our 5th year of operation, we’ve had many defining and exciting moments over the years. A main driver in these MOMA moments is the impact we strive to make every day. Hear from two of our MOMAtes, Salah Nabhan and Kate Hardy, on what has stood out for them and what’s most thrilling on the horizon. 

#ICYMI, MOMA started the year off with some big updates on MOMA-341, MOMA-313, and our new MOMA-989, which was exclusively in-licensed. We’re thrilled to have the opportunity to make some impactful progress across our pipeline this year and next. Read more below. 

Excited to be on the ground at #JPM25 this week following MOMA Therapeutics' recent pipeline updates, including an exclusive in-licensing agreement for MOMA-989, a clinical path for MOMA-341, and more on MOMA-313.   What a way to start off the year! Looking forward to connecting with industry members and friends.

Today, the MOMA team is excited to share a corporate update, including news of an exclusive in-licensing agreement for a development-stage, next-generation, and selective PARP1 inhibitor, now known as MOMA-989, a clinical path for MOMA-341, and updates on MOMA-313. Adding MOMA-989 to our portfolio is another step in strengthening our focus on developing truly impactful #precisiontherapies, and we’re excited for what’s to come across our pipeline. Read more on the updates: https://lnkd.in/eRuzz4RT

We’re winding down the year but not winding down our spirit! For the past few months, MOMAtes have been involved with My Brothers Table, working to support local families in need by putting together lunch kits. We're proud of the work this team does to uplift our community. Take a look at the roundup of impact we had this year below!

This week, we slowed down to recognize the strength of this team and emphasize why we’re here. This #Thanksgiving, we are grateful for this space we created together, and the meaningful output of #precisionmedicines for patients. Here’s to more shared meals, ideas, and milestones ahead. Happy Thanksgiving from MOMA! 🦃

At MOMA, we’re thrilled to be actively involved in the community! Today, our Chief People Officer, Adam Thomas (he/him), will present at the Gloucester Marine Genomics Institute’s 2024 Education & Workforce Development Conference. This great annual event brings together leaders committed to expanding access to STEM careers for people of all backgrounds and pathways. Join us as we connect with others who are dedicated to building a more equitable future in STEM! https://lnkd.in/eSNRpJBx

MOMA Chief People and Experience Officer, Adam Thomas (he/him) will be at LEAP HR Emerging Biopharma conference in Boston next week. We’re excited to see him converse with other industry leaders in a panel on navigating the remote or hybrid work life at an up-and-coming biotech organization. Learn more and join the event at: https://lnkd.in/exXV257